Lumox selected for Biotech Booster: a €200,000 step towards patients

Lumox co-founders Irati Beltrán Hernández and Sebas Pronk pitching on stage during the Biotech Booster programme

Lumox has been selected for the national Biotech Booster programme and awarded €200,000 to prepare its light-activated cancer medicine for the road to the clinic.

One of the biggest steps in developing a new cancer medicine is proving that it can be made at a larger scale. Without that proof, no matter how promising the science, patients will never see it.

“We want to get ready to use our medicine in patients,” says co-founder Dr. Sebas Pronk. “This will still take some time, but obtaining proof-of-concept that our medicine can be produced on a larger scale is essential. The Biotech Booster programme makes this possible.”

From the lab bench to the clinic

With the Biotech Booster support, the Lumox team will improve the production process of its medicine in preparation for human trials, conduct in vitro toxicity and pharmacology studies, and perform efficacy testing. The therapy, Rapid PhotoTherapy, combines tumor-seeking nanobodies with a light-activated drug: after injection, the medicine automatically finds the tumor, where harmless light switches it on to destroy cancer cells while preserving the surrounding tissue.

From the lab bench, to cats with cancer, and eventually to patients: every step brings Lumox closer to what matters most, treating cancer without the devastating side effects.

Lumox co-founders Irati Beltrán Hernández and Sebas Pronk pitching on stage during the Biotech Booster programme
Co-founders Irati Beltrán Hernández and Sebas Pronk present Lumox’ mission: revolutionizing cancer treatment.

About Lumox — Lumox is a Utrecht-based biotech company developing Selective PhotoTherapy: a new generation of precision cancer medicines that combine a tumor-seeking nanobody with a light-activatable drug. The medicine remains inactive in the body until it is activated with harmless light, exactly where and when it is needed, killing cancer cells while sparing healthy tissue. Lumox builds on more than a decade of research at Utrecht University and works closely with UMC Utrecht. More information: www.lumoxbiotech.com

Cristianne Rijcken joins Lumox as co-founder and Chief Development Officer

A major step forward for Lumox: experienced biotech entrepreneur and drug developer Dr. Cristianne Rijcken is joining Lumox as co-founder and Chief Development Officer (CDO), bringing firsthand experience in taking an innovative drug from the lab all the way to Phase II clinical trials.

Cristianne is no stranger to building biotech companies and translating promising science into real medicines. As founder and CSO of Cristal Therapeutics, she helped take the company’s technology from its origins in academic research at Utrecht University through development and into Phase II clinical trials.

That experience is highly relevant to Lumox as we move into our next chapter. We have spent years developing the science behind Selective PhotoTherapy. Now comes the challenge of turning that science into a medicine that can reach patients.

Experience for the next chapter

With Cristianne joining as co-founder and CDO, Lumox adds deep experience in drug development, clinical translation and building biotech companies.

Together, the three founders bring complementary expertise: from inventing and developing the technology to translating it into a clinical programme and building the company behind it.

The science is there. Now, with the right team in place, it is time to take the next steps.

Co-founders Sebas Pronk, Irati Beltán Hernández and Cristianne Rijcken (right) at the Bridge for Impact event in Utrecht.

About Lumox — Lumox is a Utrecht-based biotech company developing Selective PhotoTherapy: a new generation of precision cancer medicines that combine a tumor-seeking nanobody with a light-activatable drug. The medicine remains inactive in the body until it is activated with harmless light, exactly where and when it is needed, killing cancer cells while sparing healthy tissue. Lumox builds on more than a decade of research at Utrecht University and works closely with UMC Utrecht. More information: www.lumoxbiotech.com